A Study Comparing Urolift and TURP Ahead of Radiotherapy in Men With Urinary Symptoms Secondary to Prostate Enlargement (CO-STAR)
Prostate Cancer
About this trial
This is an interventional other trial for Prostate Cancer
Eligibility Criteria
Inclusion Criteria: Men undergoing prostate radiotherapy for prostate cancer Patients with moderate to severe and/or bothersome lower urinary tract symptoms secondary to prostate enlargement and/or an obstructive flow rate Patients willing and able to provide written informed consent for the study. Exclusion Criteria: Extensive locally advanced disease Unfavourable anatomical features (e.g. large middle lobe, for UroLift this requires advanced techniques that have not been fully evaluated in the benign setting(11) Prostates over 100g (as per manufacturer's guidelines) Co-morbidities precluding surgical intervention Prior prostate cancer treatment (including radical prostatectomy, focal therapy i.e. brachytherapy / high intensity focal ultrasound) Prior surgical intervention for benign prostatic hyperplasia (including prior UroLift / TURP / other prostate de-obstructing procedures) Urinary symptoms not due to prostatic enlargement as primary cause (i.e. neurological disease) Patients with complications of prostate enlargement including catheter dependent retention, recurrent urinary tract infections, bladder stones, obstructive uropathy Urinary incontinence due to an incompetent sphincter Co-existing gross haematuria Current active urinary tract infection
Sites / Locations
- St Georges University Hospital
- Kathie WongRecruiting
- The Royal Marsden NHS Foundation TrustRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
TURP
UroLift
Transurethral Resection of Prostate
UroLift